The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as cardiovascular disease, inflammatory disease and autoimmune disease and cell proliferative disorder. Formula (I): Y1 is selected from the group consisting of: (a) and (b) Z is O or S D1 is selected from the group consisting of: (a) phenyl substituted with a group, R5 (b) naphthyl (c) C3-8cycloalkyl (d) heteroaryl (e) heterocyclyl.Linvention concerne des composés représentés par les formules I-V et des tautomères de ceux-ci, ou des sels pharmaceutiquement acceptables, des esters et des promédicaments de ceux-ci qui constituent des inhibiteurs de la syk kinase. Linvention concerne aussi des produits intermédiaires utilisés dans la fabrication de tels composés, la préparation dun tel composé, des compositions pharmaceutiques contenant un tel composé, des procédés dinhibition de lactivité de la syk kinase, des procédés dinhibition de lagrégation plaquettaire et des procédés destinés à prévenir ou à traiter des états pathologiques dus au moins en partie à lactivité de la syk kinase, tels quune thrombose indésirable et un lymphome malin non hodgkinien.
